Bruker Corporation (NASDAQ:BRKR) VP Mark Munch sold 21,061 shares of Bruker Corporation stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $29.97, for a total value of $631,198.17. Following the transaction, the vice president now owns 60,524 shares of the company’s stock, valued at approximately $1,813,904.28. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Bruker Corporation (BRKR) traded up 0.283% during midday trading on Thursday, reaching $30.085. The company had a trading volume of 285,505 shares. Bruker Corporation has a 1-year low of $19.59 and a 1-year high of $30.22. The firm’s 50 day moving average is $28.34 and its 200 day moving average is $26.37. The stock has a market capitalization of $4.77 billion, a PE ratio of 29.995 and a beta of 1.10.

Bruker Corporation (NASDAQ:BRKR) last issued its earnings results on Thursday, August 3rd. The medical research company reported $0.23 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.03. Bruker Corporation had a net margin of 9.65% and a return on equity of 26.66%. The company had revenue of $414.90 million during the quarter, compared to analysts’ expectations of $384.75 million. During the same period last year, the company posted $0.20 earnings per share. The firm’s quarterly revenue was up 11.6% compared to the same quarter last year. On average, equities analysts anticipate that Bruker Corporation will post $1.12 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 22nd. Shareholders of record on Tuesday, September 5th will be issued a $0.04 dividend. The ex-dividend date is Thursday, August 31st. This represents a $0.16 dividend on an annualized basis and a yield of 0.53%. Bruker Corporation’s dividend payout ratio (DPR) is presently 16.00%.

COPYRIGHT VIOLATION WARNING: “Bruker Corporation (BRKR) VP Mark Munch Sells 21,061 Shares” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2017/09/14/bruker-corporation-brkr-vp-mark-munch-sells-21061-shares.html.

A number of institutional investors have recently modified their holdings of BRKR. Teachers Advisors LLC increased its holdings in Bruker Corporation by 19.4% in the fourth quarter. Teachers Advisors LLC now owns 123,004 shares of the medical research company’s stock valued at $2,605,000 after buying an additional 19,995 shares in the last quarter. Capstone Asset Management Co. purchased a new position in Bruker Corporation in the first quarter valued at about $203,000. Wells Fargo & Company MN increased its holdings in Bruker Corporation by 7.0% in the first quarter. Wells Fargo & Company MN now owns 849,870 shares of the medical research company’s stock valued at $19,826,000 after buying an additional 55,454 shares in the last quarter. Canada Pension Plan Investment Board increased its holdings in Bruker Corporation by 648.9% in the first quarter. Canada Pension Plan Investment Board now owns 70,400 shares of the medical research company’s stock valued at $1,642,000 after buying an additional 61,000 shares in the last quarter. Finally, BNP Paribas Arbitrage SA increased its holdings in Bruker Corporation by 2,913.0% in the first quarter. BNP Paribas Arbitrage SA now owns 48,841 shares of the medical research company’s stock valued at $1,139,000 after buying an additional 47,220 shares in the last quarter. 65.42% of the stock is owned by institutional investors.

A number of equities analysts have weighed in on the company. BidaskClub lowered Bruker Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Cowen and Company restated a “hold” rating and set a $29.00 target price on shares of Bruker Corporation in a research report on Friday, July 14th. Barclays PLC restated an “equal weight” rating and set a $30.00 target price (up from $26.00) on shares of Bruker Corporation in a research report on Monday, July 17th. Zacks Investment Research upgraded Bruker Corporation from a “hold” rating to a “buy” rating and set a $33.00 target price on the stock in a research report on Thursday, July 6th. Finally, Wells Fargo & Company cut Bruker Corporation from a “market perform” rating to an “underperform” rating in a research report on Wednesday, July 12th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Hold” and an average price target of $27.00.

About Bruker Corporation

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Insider Buying and Selling by Quarter for Bruker Corporation (NASDAQ:BRKR)

Receive News & Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.